Buy on the Dip Prospects: May 27 Edition

• 50 ETFs made it to the buy on the dip prospects list. The U.S. stock market extended its strong performance. The month-on-month gains were primarily driven by a combination of factors indicating easing geopolitical tensions, robust corporate earnings, and continued enthusiasm for AI.

• Direxion Daily GOOGL Bull 1.5X Shares (GGLL A) topped the buy on the dip list with over 300% annual return. Google shares experienced short-term dips due to investor concerns over the massive costs of scaling AI infrastructure and data centers, combined with geopolitical tensions, and regulatory hurdles in the European Union.

• Several precious metals ETFs like Amplify Junior Silver Miners ETF (SILJ C+), Aberdeen Standard Physical Silver (SIVR C+), VanEck Vectors Junior Gold Miners ETF (GDXJ B+), and VanEck Vectors Gold Miners ETF (GDX B+) featured on the buy on the dip list. Prices fell sharply due to a strengthening US Dollar, spiking inflation expectations, and rising bond yields. As geopolitical tensions pushed crude oil higher, markets priced in the possibility of the Federal Reserve keeping interest rates higher for longer, dampening demand for non-yielding assets.

• GraniteShares 2x Long NVDA Daily ETF (NVDL B+) and T-REX 2X Long NVIDIA Daily Target ETF (NVDX A) were buy on the dip contenders. Nvidia (NASDAQ: NVDA) shares experienced pullbacks recently primarily due to the “law of large numbers,” as astronomical expectations made it difficult for investors to get excited even by record-breaking earnings. Profit-taking, mounting cloud-competitor threats, and macro-headwinds also pressured the stock.

• Several biotechnology-focused ETFs such as SPDR S&P Biotech ETF (XBI A) and iShares Nasdaq Biotechnology ETF (IBB A-) also made it to the buy on the dip list. The US biotech sector recently experienced a downturn primarily driven by macroeconomic policy uncertainty, particularly fears over proposed import tariffs, fluctuating interest rates that reduced risk appetite for unprofitable firms, and a broader market rotation away from speculative drug discovery toward established tech sectors.

• Emerging market funds like SPDR Portfolio Emerging Markets ETF (SPEM ), Vanguard FTSE Emerging Markets ETF (VWO A), and Schwab Emerging Markets Equity ETF (SCHE A-) also made it to the list. Emerging markets fell due to geopolitical turmoil, an energy shock, and a surging U.S. dollar. Check out our Emerging Markets Equities ETFs’ list here: https://etfdb.com/etfdb-category/emerging-markets-equities/

_To compare this month’s list with the one published April 15th, click “here.”: https://etfdb.com/news/2026/04/15/buy-on-the-dip-prospets-apr-15-edit/

Please note that this list is updated on a monthly basis.

For more ETF analysis, make sure to sign up for our free ETF newsletter.

Disclosure: No positions at time of writing.